OCS-01 failed to meet the primary endpoint of improving visual acuity in both Phase 3 DIAMOND studies. ・The treatment reduced ...
8d
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The ...
Oculis Holding AG shares plunged >35% after both Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema failed primary ...
Oculis will not pursue FDA approval for OCS-01, an eye drop for diabetic macular edema, after it failed to meet the primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results